Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Shares Outstanding (Diluted Average) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $61.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.37% to $61.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.4 million through Dec 2025, up 1.37% year-over-year, with the annual reading at $61.4 million for FY2025, 1.37% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $61.4 million at Pliant Therapeutics, roughly flat from $61.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $61.4 million in Q2 2025, with the low at $35.6 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $50.8 million, with a median of $58.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 1778.37% in 2021, then grew 1.17% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $35.8 million in 2021, then rose by 17.21% to $42.0 million in 2022, then surged by 39.75% to $58.7 million in 2023, then grew by 3.1% to $60.5 million in 2024, then grew by 1.37% to $61.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $61.4 million, $61.3 million, and $61.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.